Dr Li on the Evolution of HER2-Targeted Therapy in HER2+ CRC

Daneng Li, MD, discusses the evolution of treating patients with HER2-positive colorectal cancer and highlights the effects of implementing HER2-targeted therapy in this patient population.

Related Keywords

Daneng Li ,Neuroendocrine Tumor Program ,Department Of Medical Oncology Therapeutics Research ,Medical Oncology ,Therapeutics Research ,City Of Hope ,Onclive Tv ,Colorectal Cancer ,